Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
113.01(c) 112.34(c) 114(c) 116.24(c) 115.42(c) Last
5 570 097 4 114 199 4 884 039 6 263 789 4 333 453 Volume
+0.58% -0.59% +1.48% +1.96% -0.71% Change
More quotes
Financials (USD)
Sales 2021 55 834 M - -
Net income 2021 13 933 M - -
Net Debt 2021 66 251 M - -
P/E ratio 2021 14,7x
Yield 2021 4,41%
Sales 2022 59 245 M - -
Net income 2022 17 734 M - -
Net Debt 2022 52 205 M - -
P/E ratio 2022 11,5x
Yield 2022 4,75%
Capitalization 204 B 204 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,32x
Nbr of Employees 48 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human... 
Sector
Pharmaceuticals
Calendar
06/11Presentation
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ABBVIE INC.
06/11AbbVie Sees Continued Positive Results for Leukemia Treatment
DJ
06/11ABBVIE  : Says Follow-Up Analysis on Venetoclax Showed Sustained Progression-Fre..
MT
06/11ABBVIE  : New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combinati..
PR
06/11PRESS RELEASE : Roche announces data at EHA2021 -2-
DJ
06/09ABBVIE  : Allergan Aesthetics and BOTOX Cosmetic (onabotulinumtoxinA) Put Real S..
AQ
06/09ABBVIE  : Working With Caraway Therapeutics to Develop Small Molecule Therapeuti..
MT
06/08ABBVIE  : CAPTIVATE Study Shows an IMBRUVICA (ibrutinib) Plus VENCLEXTA/VENCLYXT..
AQ
06/08ABBVIE  : Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real ..
PR
06/07ABBVIE  : Reports Encouraging Data From Phase 2 Study of Imbruvica/Venclexta Com..
MT
06/07First New Alzheimer's Drug in Nearly Two Decades Is Approved by FDA -- 3rd Up..
DJ
06/07ABBVIE  : Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatme..
AQ
06/07ABBVIE  : Results from IMBRUVICA (ibrutinib) RESONATE-2 Study Provide Up to Seve..
AQ
06/07ASTRAZENECA  : Calquence Beats AbbVie Drug in Late-Stage Blood Cancer Study
MT
06/03ABBVIE  : to Present Analysis Evaluating Continuous RINVOQ (upadacitinib) Treatm..
AQ
06/03ABBVIE  : Phase 3 Maintenance Results Show Patients with Crohn's Disease Receivi..
AQ
More news
News in other languages on ABBVIE INC.
06/11ROCHE : Daten zu Venclexta/Venclyxto untermauern Wirksamkeit bei Leukämie
06/03COVID  : Paesi più ricchi si sono assicurati vaccini fino al 2023
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/25ROCHE  : approbation pour Venclyxto par Bruxelles
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 122,85 $
Last Close Price 115,42 $
Spread / Highest target 24,8%
Spread / Average Target 6,44%
Spread / Lowest Target -10,8%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.7.72%203 857
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ELI LILLY AND COMPANY32.72%203 704